Genentech Announces Final Results from Phase 3 AVAglio Study in People with Glioblastoma
June 01, 2013 at 19:09 PM EDT
Genentech, a member of the Roche Group (OTC: RHHBY ), today announced final results from the Phase III AVAglio study in people with newly diagnosed glioblastoma, the most common and aggressive form
